FDA-Approved MASH drug gets Real-World test in pakistan

NCT ID NCT07249788

Recruiting now Disease control Sponsor: Nabiqasim Industries (Pvt) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this specific population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Resmiterom (a drug for MASH, already FDA-approved)
What this could lead to: If successful, this could confirm resmiterom's safety and effectiveness for MASH in a broader population, supporting its use as a standard treatment.
What could go wrong: This is a Phase 4 study, so the drug is already approved, but it's open-label (no placebo) and limited to one country, which may affect how well results apply elsewhere. Side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Locations

Liver transplant center, Holy family hospital
RECRUITING

Rawalpindi, Punjab Province, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.